PartnershipMay 11, 2026, 06:46 AM
GSK partners with SBP Group for bepirovirsen launch in China
AI Summary
GSK plc announced an exclusive strategic collaboration with Sino Biopharmaceutical (SBP Group), through its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), to accelerate the launch of bepirovirsen in mainland China. Bepirovirsen is a potential first-in-class treatment for chronic hepatitis B (CHB), currently under priority regulatory review in China. CTTQ will be responsible for importation, distribution, hospital access, and promotional activities, leveraging its broad commercial footprint covering over 5,000 medical centers. This partnership aims to address chronic hepatitis B, which affects 75 million people in China and is a national health priority.
Key Highlights
- GSK entered an exclusive strategic collaboration with SBP Group/CTTQ for bepirovirsen in mainland China.
- Bepirovirsen is a potential first-in-class treatment for chronic hepatitis B (CHB).
- CTTQ provides scaled access to over 5,000 medical centers in China.
- Chronic hepatitis B affects 75 million people in China and causes approximately 450,000 deaths annually.
- Bepirovirsen received Breakthrough Therapy designation in China in August 2021 and Priority Review in April 2026.
- CTTQ will purchase bepirovirsen from GSK under agreed supply terms for an initial term of 5.5 years.
- GSK gains the ability to review SBP Group's early-stage pipeline for potential collaboration opportunities outside China.